521 related articles for article (PubMed ID: 29451055)
1. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
[TBL] [Abstract][Full Text] [Related]
2. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
3. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer.
Lehrnbecher T; Stanescu A; Kühl J
Infection; 2002 Jan; 30(1):17-21. PubMed ID: 11876510
[TBL] [Abstract][Full Text] [Related]
4. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study.
Miedema KG; Tissing WJ; Abbink FC; Ball LM; Michiels EM; van Vliet MJ; de Vries WY; Kamps WA; Norbruis OF; Fiocco M; de Groot-Kruseman HA; van de Wetering MD; de Bont ES
Eur J Cancer; 2016 Jan; 53():16-24. PubMed ID: 26700076
[TBL] [Abstract][Full Text] [Related]
6. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
Paret R; Le Bourgeois A; Guillerm G; Tessoulin B; Rezig S; Gastinne T; Couturier MA; Boutoille D; Lecomte R; Ader F; Le Gouill S; Ansart S; Talarmin JP; Gaborit B
J Antimicrob Chemother; 2022 Aug; 77(9):2546-2556. PubMed ID: 35748614
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
Van de Wyngaert Z; Berthon C; Debarri H; Bories C; Bonnet S; Nudel M; Carpentier B; Legrand C; Barbieux S; Chauvet P; Simonnet A; Willaume A; Bossard JB; Renaud L; Wattebled KJ; Escure G; Branche N; Arib I; Titecat M; Quesnel B; Alfandari S
Int J Antimicrob Agents; 2019 Jun; 53(6):781-788. PubMed ID: 30831232
[TBL] [Abstract][Full Text] [Related]
8. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
[TBL] [Abstract][Full Text] [Related]
9. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
10. Is current initial empirical antibiotherapy appropriate to treat bloodstream infections in short-duration chemo-induced febrile neutropenia?
Joncour A; Puyade M; Michaud A; Tourani JM; Cazenave-Roblot F; Rammaert B
Support Care Cancer; 2020 Jul; 28(7):3103-3111. PubMed ID: 31667604
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study.
Al-Tawfiq JA; Hinedi K; Khairallah H; Saadeh B; Abbasi S; Noureen M; Raza S; Alkhatti A
J Infect Public Health; 2019; 12(3):364-366. PubMed ID: 30594483
[TBL] [Abstract][Full Text] [Related]
14. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
15. [Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society].
Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
Med Klin (Munich); 1994 Mar; 89(3):114-23. PubMed ID: 8196571
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].
Masmoudi S; Khanfir A; Maalej-Mezghan S; Hammami A; Frikha M
Tunis Med; 2015 Apr; 93(4):217-22. PubMed ID: 26375737
[TBL] [Abstract][Full Text] [Related]
17. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?
Micol JB; Chahine C; Woerther PL; Ghez D; Netzer F; Dufour C; Merad M; Blot F; Chachaty E; de Botton S; Gachot B
Clin Microbiol Infect; 2014 Jul; 20(7):O453-5. PubMed ID: 24313354
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.
Jeddi R; Achour M; Amor RB; Aissaoui L; Bouterâa W; Kacem K; Lakhal RB; Abid HB; BelHadjAli Z; Turki A; Meddeb B
Hematology; 2010 Feb; 15(1):28-32. PubMed ID: 20132659
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition.
Jones GR; Konsler GK; Dunaway RP; Gold SH; Cooper HA; Wells RJ
J Pediatr; 1994 May; 124(5 Pt 1):703-8. PubMed ID: 8176555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
